Oxford, UK; Sensyne Health plc (LSE: SENS) (the “Company”), the British clinical AI technology company, will announce its full year results for the 12 months ended 30 April 2019 on Monday, 7 October 2019.
Lord Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will host a briefing for analysts at 12.00pm BST on the day of the results at 85 Gresham Street, London, EC2R 7HE.
A live webcast of the meeting, with the presentation slides, will be available via the Company website.
For more information please contact:
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0)20 7418 8900
Dr Christopher Golden
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology'.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com